About aTyr Pharma (NASDAQ:LIFE)
aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.
Industry, Sector and Symbol
Sub-IndustryLife Sciences Tools & Services
Trailing P/E Ratio-1.56084656084656
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Book Value$2.65 per share
Price / Book1.11
Return on Equity-84.85%
Return on Assets-62.00%
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.07. View aTyr Pharma's Earnings History.
When will aTyr Pharma make its next earnings announcement?
Where is aTyr Pharma's stock going? Where will aTyr Pharma's stock price be in 2018?
3 analysts have issued 1 year price objectives for aTyr Pharma's shares. Their forecasts range from $4.00 to $7.00. On average, they expect aTyr Pharma's stock price to reach $5.50 in the next year. View Analyst Ratings for aTyr Pharma.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include XBiotech (XBIT), Allena Pharmaceuticals (ALNA), Immune Design (IMDZ), Teligent (TLGT), vTv Therapeutics (VTVT), Intec Pharma (NTEC), Sierra Oncology (SRRA), Galectin Therapeutics (GALT), Verastem (VSTM), Axovant Sciences (AXON), Aldeyra Therapeutics (ALDX), Tetraphase Pharmaceuticals (TTPH), Pluristem Therapeutics (PSTI), Fennec Pharmaceuticals (FENC), Acer Therapeutics (ACER), Mediwound (MDWD), ContraFect (CFRX) and Checkpoint Therapeutics (CKPT).
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- John K. Clarke, Independent Chairman of the Board (Age 63)
- Sanjay S. Shukla M.D., President, Chief Executive Officer, Chief Medical Officer (Age 45)
- John T. Blake, Senior Vice President - Finance (Age 40)
- David John King Ph.D., Senior Vice President - Research (Age 58)
- Grove Matsuoka, Senior Vice President, Product Programs and Planning (Age 58)
- Ashraf Amanullah Ph.D., Vice President, Biologics Development and Manufacturing (Age 49)
- Timothy P. Coughlin CPA, Director (Age 50)
- Jeffrey S. Hatfield, Director
- John D. Mendlein Ph.D., Director (Age 57)
- Srinivas Akkaraju M.D. Ph.D., Independent Director (Age 48)
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
Has aTyr Pharma been receiving favorable news coverage?
Headlines about LIFE stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. aTyr Pharma earned a coverage optimism score of 0.19 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 45.87 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are aTyr Pharma's major shareholders?
aTyr Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Viking Global Investors LP (4.65%), Artal Group S.A. (1.68%), BlackRock Inc. (1.23%), Renaissance Technologies LLC (0.94%) and Deutsche Bank AG (0.19%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.
Which major investors are selling aTyr Pharma stock?
Which major investors are buying aTyr Pharma stock?
LIFE stock was purchased by a variety of institutional investors in the last quarter, including Artal Group S.A., Renaissance Technologies LLC and Deutsche Bank AG. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, Grove Matsuoka, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $2.95.
How big of a company is aTyr Pharma?
aTyr Pharma has a market capitalization of $86.41 million. The biotechnology company earns $-57,850,000.00 in net income (profit) each year or ($1.89) on an earnings per share basis. aTyr Pharma employs 58 workers across the globe.
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 John Hopkins Court Suite 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (LIFE)MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
aTyr Pharma (NASDAQ:LIFE) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Hold||Hold||Hold||Hold|
|Consensus Rating Score: ||2.00||2.00||2.25||2.25|
|Ratings Breakdown: ||1 Sell Rating(s)|
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|1 Sell Rating(s)|
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$5.50||$5.00||$5.00||$4.46|
|Price Target Upside: ||86.44% upside||42.86% upside||78.57% upside||59.38% upside|
aTyr Pharma (NASDAQ:LIFE) Consensus Price Target History
aTyr Pharma (NASDAQ:LIFE) Analyst Ratings History
(Data available from 3/22/2016 forward)
aTyr Pharma (NASDAQ:LIFE) Earnings History and Estimates Chart
aTyr Pharma (NASDAQ LIFE) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/5/2013||Q313||$0.97||$1.02||$926.10 million||$936.00 million||View||N/A|
|7/31/2013||Q2 2013||$0.96||$0.72||$952.06 million||$944.00 million||View||N/A|
|5/2/2013||Q1 2013||$1.04||$1.07||$958.56 million||$963.00 million||View||N/A|
|2/4/2013||Q4 2012||$1.11||$1.11||$988.85 million||$998.90 million||View||N/A|
|11/1/2012||Q312||$0.89||$0.92||$907.91 million||$911.00 million||View||N/A|
aTyr Pharma (NASDAQ:LIFE) Earnings Estimates
2018 EPS Consensus Estimate: ($1.43)
2019 EPS Consensus Estimate: ($1.57)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com
aTyr Pharma (NASDAQ LIFE) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 58.65%
aTyr Pharma (NASDAQ LIFE) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/8/2018||Ashraf Amanullah||Insider||Sell||1,402||$3.40||$4,766.80|| |
|8/31/2017||John Mendlein||CEO||Buy||37,736||$2.65||$100,000.40|| |
|8/31/2017||Paul Schimmel||Director||Buy||94,336||$2.65||$249,990.40||40,440|| |
|4/24/2017||John Mendlein||CEO||Buy||124||$3.00||$372.00||327,647|| |
|4/20/2017||John Mendlein||CEO||Buy||2,552||$3.00||$7,656.00||325,971|| |
|12/21/2016||Paul Schimmel||Director||Buy||25,000||$2.28||$57,000.00||40,440|| |
|12/20/2016||Ashraf Amanullah||VP||Buy||11,000||$2.25||$24,750.00||11,000|| |
|12/19/2016||John Mendlein||CEO||Buy||69,000||$2.20||$151,800.00|| |
|12/16/2016||Paul Schimmel||Director||Buy||50,000||$2.48||$124,000.00||40,440|| |
|5/11/2016||Grove Matsuoka||Insider||Buy||12,412||$3.04||$37,732.48||2,412|| |
|4/14/2016||Paul Schimmel||Director||Buy||66,219||$4.18||$276,795.42||53,012|| |
|4/13/2016||Paul Schimmel||Director||Buy||9,835||$3.85||$37,864.75||20,412|| |
|4/12/2016||Paul Schimmel||Director||Buy||9,127||$3.71||$33,861.17||20,412|| |
|4/11/2016||Paul Schimmel||Director||Buy||32,659||$3.57||$116,592.63||214,931|| |
|4/8/2016||Paul Schimmel||Director||Buy||85,000||$3.22||$273,700.00||187,572|| |
|4/7/2016||Paul Schimmel||Director||Buy||40,000||$3.19||$127,600.00||102,572|| |
|4/6/2016||Paul Schimmel||Director||Buy||25,000||$3.20||$80,000.00||62,572|| |
|4/5/2016||John Mendlein||CEO||Buy||2,500||$3.55||$8,875.00||248,471|| |
|4/5/2016||Paul Schimmel||Director||Buy||25,000||$3.52||$88,000.00||37,572|| |
|5/12/2015||James E Flynn||Insider||Buy||50,000||$14.00||$700,000.00|| |
|5/12/2015||Sofinnova Venture Partners Ix,||Major Shareholder||Buy||320,000||$14.00||$4,480,000.00|| |
|5/29/2013||David C Uprichard||Director||Sell||2,010||$74.04||$148,820.40|| |
|5/28/2013||John A Cottingham||Insider||Sell||60,000||$74.03||$4,441,800.00|| |
aTyr Pharma (NASDAQ LIFE) News Headlines
|William Blair Equities Analysts Lift Earnings Estimates for aTyr Pharma Inc (LIFE)|
www.americanbankingnews.com - March 22 at 8:45 AM
|aTyr Pharma Inc Expected to Earn Q1 2019 Earnings of ($0.37) Per Share (LIFE)|
www.americanbankingnews.com - March 21 at 11:01 AM
|Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT|
finance.yahoo.com - March 20 at 4:39 PM
|aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update|
globenewswire.com - March 20 at 9:18 AM
|aTyr Pharma, Inc. to Host Earnings Call|
finance.yahoo.com - March 20 at 9:18 AM
|aTyr Pharma (LIFE) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - March 10 at 3:42 PM
|Are Big Pharma Using Corporate Tax Savings to Lower Drugs Costs?|
www.zacks.com - March 10 at 9:08 AM
|aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018|
finance.yahoo.com - March 7 at 9:14 AM
|aTyr Pharma (LIFE) Scheduled to Post Quarterly Earnings on Wednesday|
www.americanbankingnews.com - March 7 at 2:14 AM
|Contrasting aTyr Pharma (LIFE) and Oncomed Pharmaceuticals (OMED)|
www.americanbankingnews.com - March 4 at 5:18 PM
|aTyr Pharma to Present at Two Upcoming Investor Conferences in March|
finance.yahoo.com - March 1 at 8:53 AM
|aTyr Pharma Inc (LIFE) Receives Average Recommendation of "Hold" from Brokerages|
www.americanbankingnews.com - March 1 at 5:30 AM
|aTyr Pharma (LIFE) Rating Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - February 24 at 9:48 PM
|JPMorgan Chase & Co. Lowers aTyr Pharma (LIFE) to Underweight|
www.americanbankingnews.com - February 14 at 10:38 AM
|Zacks: Analysts Anticipate aTyr Pharma, Inc. (LIFE) Will Announce Earnings of -$0.43 Per Share|
www.americanbankingnews.com - February 10 at 9:18 PM
|Q1 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By William Blair (LIFE)|
www.americanbankingnews.com - February 8 at 9:18 AM
|Achieve Life Sciences (ACHV) vs. aTyr Pharma (LIFE) Head-To-Head Analysis|
www.americanbankingnews.com - February 5 at 11:14 PM
|aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Analysts|
www.americanbankingnews.com - February 4 at 5:30 AM
|Zacks: Analysts Expect aTyr Pharma, Inc. (LIFE) Will Post Earnings of -$0.43 Per Share|
www.americanbankingnews.com - January 24 at 9:24 PM
|aTyr Pharma (LIFE) Downgraded to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 17 at 6:10 AM
|aTyr Pharma, Inc. (LIFE) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - January 10 at 8:14 AM
| Brokerages Anticipate aTyr Pharma, Inc. (LIFE) to Post -$0.43 Earnings Per Share|
www.americanbankingnews.com - January 7 at 5:26 PM
|aTyr Pharma (LIFE) versus Nektar Therapeutics (NKTR) Head-To-Head Review|
www.americanbankingnews.com - January 5 at 9:16 PM
|aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium - GlobeNewswire (press release)|
globenewswire.com - December 23 at 5:23 AM
|aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium |
finance.yahoo.com - December 21 at 9:19 AM
|aTyr Pharma, Inc. (LIFE) Given Consensus Rating of "Hold" by Analysts|
www.americanbankingnews.com - December 16 at 8:46 AM
|aTyr Pharma to Participate at the BMO Prescriptions for Success Healthcare Conference|
finance.yahoo.com - December 7 at 9:24 AM
|Zacks: Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.44 Earnings Per Share|
www.americanbankingnews.com - December 4 at 3:14 PM
|aTyr Pharma (LIFE) Cut to "Strong Sell" at ValuEngine|
www.americanbankingnews.com - December 3 at 8:34 AM
|aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc ... - GlobeNewswire (press release)|
globenewswire.com - November 28 at 10:00 AM
|aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)|
finance.yahoo.com - November 27 at 5:06 PM
|aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - November 21 at 8:16 AM
|aTyr Pharma, Inc. (LIFE) Upgraded to "Buy" by Zacks Investment Research|
www.americanbankingnews.com - November 18 at 6:40 AM
|FY2017 EPS Estimates for aTyr Pharma, Inc. Raised by William Blair (LIFE)|
www.americanbankingnews.com - November 17 at 8:52 PM
|Atyr Pharma reports 3Q loss|
finance.yahoo.com - November 17 at 1:16 PM
|aTyr Pharma, Inc. (LIFE) Posts Earnings Results, Beats Expectations By $0.07 EPS|
www.americanbankingnews.com - November 15 at 12:43 PM
|aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update - GlobeNewswire (press release)|
globenewswire.com - November 15 at 4:14 AM
|aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update|
finance.yahoo.com - November 15 at 4:14 AM
|aTyr Pharma, Inc. (LIFE) Set to Announce Quarterly Earnings on Monday|
www.americanbankingnews.com - November 6 at 6:26 AM
|aTyr Pharma Announces Leadership Transition - GlobeNewswire (press release)|
globenewswire.com - November 2 at 5:33 AM
|aTyr Pharma Announces Leadership Transition|
finance.yahoo.com - November 2 at 5:33 AM
|Head-To-Head Comparison: aTyr Pharma (LIFE) versus Its Competitors|
www.americanbankingnews.com - October 28 at 3:30 PM
|aTyr Pharma, Inc. (LIFE) Receives Average Recommendation of "Hold" from Analysts|
www.americanbankingnews.com - October 27 at 7:58 AM
|-$0.51 EPS Expected for aTyr Pharma, Inc. (LIFE) This Quarter|
www.americanbankingnews.com - October 26 at 5:26 PM
|aTyr Pharma, Inc. (LIFE) Expected to Post Earnings of -$0.51 Per Share|
www.americanbankingnews.com - October 7 at 6:26 PM
|How Should You Think About aTyr Pharma Inc’s (LIFE) Risks?|
finance.yahoo.com - October 5 at 8:18 AM
|aTyr Pharma, Inc. (LIFE) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - October 2 at 4:32 AM
|aTyr Pharma (LIFE) to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset ... - StreetInsider.com|
www.streetinsider.com - September 29 at 1:58 PM
|aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society|
finance.yahoo.com - September 27 at 10:14 AM
| Brokerages Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.53 EPS|
www.americanbankingnews.com - September 19 at 12:26 AM
aTyr Pharma (NASDAQ:LIFE) SEC Filings
This page is loading this company's SEC Filings. Please wait...
aTyr Pharma (NASDAQ:LIFE) Income Statement, Balance Sheet and Cash Flow Statement
aTyr Pharma (NASDAQ LIFE) Stock Chart for Thursday, March, 22, 2018